Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy
consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in
treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as
CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. This trial may help find out if this
approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.